| Literature DB >> 32545678 |
Ružena Čižmáriková1, Jozef Čižmárik2, Jindra Valentová1, Ladislav Habala1, Mário Markuliak1.
Abstract
Thanks to the progress made in chemical technology (particularly in the methodologies of stereoselective syntheses and analyses) along with regulatory measures, the number of new chiral drugs registered in the form of pure enantiomers has increased over the past decade. In addition, the pharmacological and pharmacokinetic properties of the individual enantiomers of already-introduced racemic drugs are being re-examined. The use of the pure enantiomer of a drug that has been used to date in the form of a racemate is called a "chiral switch". A re-examination of the properties of the pure enantiomers of racemates has taken place for local anesthetics, which represent a group of drugs which have long been used. Differences in (R) and (S)-enantiomers were found in terms of pharmacodynamic and pharmacokinetic activity as well as in toxicity. Levobupivacaine and robivacaine were introduced into practice as pure (S)-(-)-enantiomers, exhibiting more favorable properties than their (R)-(+)-stereoisomers or racemates. This overview focuses on the influence of chirality on the pharmacological and toxicological activity of local anesthetics as well as on individual HPLC and capillary electrophoresis (CE) methods used for enantioseparation and the pharmacokinetic study of individual local anesthetics with a chiral center.Entities:
Keywords: chiral; local anesthetic; pharmacokinetics; pharmacology; stereochemistry
Year: 2020 PMID: 32545678 PMCID: PMC7355888 DOI: 10.3390/molecules25122738
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Physical-chemical/pharmacokinetic properties and toxicity of some local anesthetics.
| INN 1 | pKa | Partition Coeffic. 2 | Solubility pH 7.4 | Protein Binding (%) | Half-Life | Speed on Onset | Duration | Toxicity |
|---|---|---|---|---|---|---|---|---|
| Mepivacaine | 7.6 | 21 | Moderate | 78 | 2.0–3.0 h | Fast | Intermediate | Low |
| Prilocaine | 7.9 | 25 | Moderate | 6 | 1.25h | Slow | Intermediate | Low |
| Bupivacaine | 8.1 | 346 | Very good | 95 | 2.7–3.5 h | Slow | Long | High |
| Ropivacaine | 8.1 | 115 | Very good | 94 | 1.8 h | Slow | Long | Intermediate |
| Articaine | 7.8 | 32 | Moderate | 95 | 0.5 h | Very fast | Long | Low |
| Etidocaine | 7.7 | 800 | Very good | 94 | 2.7 h | Fast | Intermediate | Intermediate |
| Lidocaine | 7.9 | 43 | Moderate | 77 | 1.5–1.8 h | Fast | Intermediate | Low |
| Procaine | 8.9 | 1.7 | Low | 6 | 30–50 s | Slow | Short | Low |
| Tetracaine | 8.2 | 221 | Very good | 76 | 2–4 min | Fast | Short | Intermediate |
1 international nonproprietary name, 2 octanol—water partition coefficient.
Figure 1Structures and stereochemistry of (R)-prilocaine (left) and (S)-prilocaine (right).
Scheme 1Cocaine (1).
Scheme 2Mepivacaine (2).
Scheme 3Prilocaine (3).
Scheme 4Bupivacaine (4) and levobupivacaine (5).
Scheme 5Ropivacaine (6).
Scheme 6IQB-9302. (7).
Scheme 7Articaine (8).
Scheme 8Etidocaine (9).
Scheme 9Carbizocaine (10).
Scheme 10Pentacaine (11).
Scheme 11Fomocaine (12).
Scheme 12Chiral derivatives (+)-O/G5 (13) and (−)-O/G3 (14) of compound (12).
Figure 2Selected metabolites of ropivacaine (6).
Scheme 13Diperodone enantiomer (19).
Figure 3Derivatives of phenylcarbamic acid.
Chiral stationary phases and mobile phases used to separate local anesthetics by HPLC.
| Chiral Stationary Phase | Mobile Phase | Chiral Local Anesthetic | Ref. |
|---|---|---|---|
| Supelcosil LC-urea | Acetonitrile | Cocaine | [ |
| Chiracel OD | Hexane/ethanol | Bupivacaine, mepivacaine, prilocaine | [ |
| Chiracel OD | Hexane/propan-2-ol | Articaine | [ |
| Chiracel OJ | Hexane/ethanol | Etidocaine | [ |
| Sumichiral OA-4700 | Hexane/dichloroethane/methanol 85:10:5 | Prilocaine | [ |
| Chirobiotic V | 5% Acetonitrile in triethylammonium acetate | Articaine | [ |
| Chirobiotic T | Methanol/acetonitrile/acetic acid/triethylamine 45:55:0.3:0.2 | Diperodon, alkoxyphenylcarbamates | [ |
| Chirobiotic TAG | Acetonitrile/methanol/acetic acid/triethylamine 80:20:0.3:0.2 | Diperodon | [ |
| β-CD | % Acetonitrile in water and 0.01% triethylamine | Carbisocaine | [ |
| β-CD, Chirobiotic TAG | Methanol/acetic acid/diethylamine | Alkoxyphenylcarbamates | [ |
| Chirex 3020 | 95% Hexane/ethanol (80:20, | Bupivacaine | [ |
Chiral selectors and background electrolyte used in capillary electrophoresis of local anesthetics.
| Chiral Selector | Part of Background Electrolyte | Chiral Local Anesthetic | Reference |
|---|---|---|---|
| Heptakis(2,6-di- | Triethanolamine | Mepivacaine, ropivacaine, bupivacaine | [ |
| Heptakis(2,6-di- | Phosphate buffer | Prilocaine | [ |
| Methyl-ß-CD | Phosphate buffer | Bupivacaine, ropivacaine | [ |
| methyl-ß-CD | Acetate buffer | Bupivacaine, ropivacaine | [ |
| Carboxymethyl, sulfobutyl ether and sulfonated-β-CD | Tris–phosphate buffer | Bupivacaine, mepivacaine, prilocaine | [ |
| Sulfobutyl ether | Acetate buffer | Bupivacaine | [ |
Selected chiral local anesthetics.
| Local Anesthetic | Total Number of Stereoisomers | Most Active Isomer | More Toxic Isomer | Used as |
|---|---|---|---|---|
| Cocaine ( | 8 | (1 | (1 | (1 |
| Mepivacaine ( | 2 | ( | NA | Racemate |
| Prilocaine ( | 2 | Comparable | ( | Racemate |
| Bupivacaine ( | 2 | Comparable | ( | ( |
| Ropivacaine ( | 2 | NA | ( | ( |
| Articaine ( | 2 | NA | NA | Racemate |
| IQB-9302 ( | 2 | NA | NA | Racemate |
| Etidocaine ( | 2 | NA | NA | Racemate |
| Carbisocaine ( | 2 | Comparable | NA | Racemate |
| Pentacaine ( | 4 | NA | NA | Racemate |
| OG/5 ( | 2 | NA | NA | Racemate |
| OG/3 ( | 2 | NA | NA | Racemate |
NA = sufficient data not available or no definite conclusions possible; comparable = differences in the activity of the respective enantiomers are insignificant.